Troponin Market

Key data points: Market size in 2027 = $1.9 billion and 2035 = $3.9 billion, growth forecast = 12.7% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in troponin market to 2035 by product type (troponin I, troponin T, troponin complex, and others), application (myocardial infarction, acute coronary syndrome, congestive heart failure, cardiomyopathy, and others), end use (hospitals, diagnostics laboratories, home care, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Troponin Market The future of the global troponin market looks promising with opportunities in the hospital, diagnostic laboratory, and home care markets. The global troponin market is expected to reach an estimated $3.9 billion by 2035 from $1.9 billion in 2027 with a CAGR of 12.7% from 2027 to 2035. The major drivers for this market are the increasing incidence of cardiovascular diseases, the rising demand for early diagnostic tests, and the growing adoption of point-of-care testing. • Lucintel forecasts that, within the product type category, troponin I is expected to witness the highest growth over the forecast period due to troponin I has higher diagnostic specificity than alternatives. • Within the end use category, diagnostic laboratories is expected to witness the highest growth over the forecast period due to increasing cardiac test requests handled by the diagnostic laboratory. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increasing cardiovascular disease and improving diagnostic test facility. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Troponin Market Troponin testing is moving toward more convenient, faster, and easier methods of diagnostic testing. We believe that during the period 2025-2027, various health care facilities will focus on improving the efficiency of their emergency services. Manufacturers, in turn, will work to adjust and create new assays to support outpatient tests. Among all the potential uses of troponin assays, Lucintel sees the highest level of technology adoption in the countries with the highest prevalence of cardiovascular disease. • High Sensitivity of Troponin Assays: The European Society of Cardiology has published guidelines recommending various hospital-based pathways for the diagnosis and management of patients with myocardial injury and myocardial seizure. Some of these pathways suggest the use of laboratory tests to rule out myocardial injury in less than 2 hours. To meet the criteria for discharging patients, some tests for measuring troponin levels suggest the use of even lower reference limits. • Point of Care Testing: To perform tests in smaller and remote health care facilities, it will no longer be necessary to rely on a central laboratory. Decentralization of testing, together with the American Heart Association's estimate of 356,000 out-of-hospital cardiac arrests in the U.S. each year, will create a strong case for purchase of emergency response systems. • Clinical Decision Integration: Hospitals are incorporating multiple sources of information such as ECGs and clinical risk scores to arrive at a diagnosis based on a troponin result. The AHA/ACC guideline expects clinicians to perform serial high sensitivity troponin measurements, and as standards evolve, these will become commonplace. • Assay Standardization: In the absence of harmonization of cardiac troponin assays, manufacturers will continue to focus on other areas including the use of surrogate standards and improving the accuracy and transparency of their assays. • Additional Cardiac Indications: The use of high sensitivity cardiac troponin assays is likely to increase with the expansion of its indications into other areas including heart and kidney disease, oncology, and surgery. There are many opportunities to increase the clinical utility of cardiac troponins. Sustained improvements in speed of results and integration of results in the clinical workflow will provide healthcare systems the opportunity to better organize and integrate their cardiology services. Greater integration of cardiology tests will allow systems to distinguish between real and pretend heart disease. Comparability of results will be important. Healthcare systems will preference these solutions in the long-term. Recent Developments in the Troponin Market Troponin markets will increase in the 2025-2027 time frame as hospitals enhance their cardiac marker testing. Lucintel reports the competition will be more on providing integrated systems and supporting evidence on clinical value. Safety and effectiveness of medical devices will remain the focal point of regulatory approval. However, the demand for cardiac point of care testing outside of central laboratories will increase. • High Sensitivity Assays Expansion: Regulatory approval in the U.S. will allow Abbott to commercialize the Alinity i high sensitivity troponin I assay. When used in an appropriate clinical setting, results from the assay may help health care professionals make decisions on ruling out a myocardial infarction with a significantly shorter length of stay and reduced need for repeat testing. • Point of Care Testing: Quidel Ortho has launched a point of care system for cardiac markers to be used in emergency settings. Systems to provide results in less than 15 minutes are being developed. Faster testing will further incentivize testing to be done outside the emergency care setting. • Systems Integration: Roche continues to integrate cardiac markers into its cobas systems. As a result, automation and integration of cardiac markers will be the focus of competition. • Clinical Pathway Standardization: Changes to international chest pain guidelines in 2025 were expected to stimulate broader adoption of clinical pathways that include high sensitivity cardiac biomarkers with accelerated time to result (e.g. zero or one hour troponins). • Multiplex Biomarker Development: The combination of cardiac, natriuretic peptides, and inflammatory markers are being researched for troponin assays, and several sponsorships for the development of cardiac biomarker panels (of 3 or more) were initiated in 2025. However, the primary barriers to the commercialization of these tests are reimbursement and evidence of clinical efficacy. In the next 5 years, the predominant driver of the troponin market would be the acceptance of health economics and clinical evidence rather than assay availability. The emphasis would be on near-patient and point-of-care testing. There would likely be a continued trend towards centralization of cardiac testing. Strategic Growth Opportunities in the Troponin Market The troponin market is transitioning to a more comprehensive market as a result of various factors including adoption of high sensitivity cardiac troponin (HCST) tests by emergency departments, consolidation of laboratory tests by various service providers, and advancement of mobile cardiac care teams. There is a growing market for HCSTs from 2024 to 2026, particularly in emergency care settings. In addition to traditional, clinic-based, cardiac care and testing, Lucintel has identified emerging opportunities for cardiac care and testing in lower-acuity settings. • Point of Care Testing: High sensitivity cardiac troponin (CTN) tests can be performed at the patient’s bedside to substantially reduce the time needed to obtain a diagnostic test in patients with acute chest pain. Accelerating the diagnostic process may reduce length of stay in the emergency department. • Cardiovascular Disease (CVD) Screening: Wide spread screening for CVD is expected to increase with the increasing number of at risk and/or high-risk patients. High sensitivity CTN tests are expected to play a significant role in screening and risk assessment for patients with diabetes mellitus and/or chronic kidney disease. • Multiplex Cardiac Panels: This involves the incorporation of natriuretic peptides and other inflammatory markers with troponin. Cardiovascular diseases are the leading cause of death worldwide, and in March 2025, the World Health Organization (WHO) estimated that approximately 17.9 million deaths were attributable to these diseases. Therefore, in the near future, integrated panels are likely to be requested in clinical laboratories. • Home-based Monitoring: In April 2025, the European Commission reported that approximately 450 million Europeans had at least one pre-existing condition. It is expected that within 3-5 years, the use of remote pathways in cardiovascular disease will lead to a sustained income from the sale of diagnostic tests, as well as from the subsequent interpretation and control of the patient’s condition. • Emerging Market Penetration: Adjustment of prices of reagents and analysers to markets with lower economic resources will lead to greater sales of these products in these regions. The World Bank (February 2025) reported that approximately 80% of the world’s population lives in countries with low and middle incomes. There will be a focus on developing the Latin American market. The use of troponin will continue to grow. However, the focus should be on ensuring that the introduction of troponin testing alters the management of a patient, as opposed to simply justifying the need for additional testing. This will predominantly be driven by regulatory changes and the prioritization of the troponin market by pharmaceutical companies. Troponin Market Drivers and Challenges Troponin market trends are impacted by various social, economic, and political factors. The increase in cardiovascular diseases has triggered the need for emergency care and quick diagnosis. Thus, the market has witnessed increased adoption in recent years. Various limitations on the market, such as accessibility and reimbursement, affect the market growth. Lucintel expects that in the near and long term, market growth will be supplemented by advancements in technology and science. The factors responsible for driving this market include: • Increase in Cardiovascular Diseases: Increasing incidences of cardiovascular diseases creates the requirement for instant diagnosis and emergency treatment. The World Health Organization estimated that in 2025, about 17.9 million individuals lost their lives because of cardiovascular diseases. It has been projected that in the short and long terms, injuries and diseases of the heart will increase because of increasing aging population, obesity, diabetes and hypertension. • High-Sensitivity Assay Technology: High sensitivity troponin assays allow laboratories to detect lower limits of cardiac biomarkers. As of 2025, multiple clinical pathways shortened the time between serial tests from several hours to as little as one hour. Older pathways recommended tests be done several hours apart. By 2030, further advances in automation and lab technologies will enhance laboratory turnaround time. The net effect will be the ability to perform cardiac biomarker tests and rule in or rule out an acute coronary syndrome within a few hours. • Emergency-Care Expansion: The growth of freestanding emergency departments and urgent care centres expanded the number of sites where cardiac testing could be performed. In 2025, the largest number of patient visits (estimated in the hundreds of millions) was reported in the emergency departments of facilities throughout the world. In the next 5 years, out-of-hospital emergency care (including mobile health care) and onsite (or near-site) emergency care will improve access to laboratory testing in remote areas. • Point-of-Care Technologies: Improvements in analyser size and speed led to greater portability. In addition, consumable and analyser separability improved the ease and speed of laboratory testing. In 2025, a number of companies launched point-of-care devices designed to deliver results in 15 minutes or less. Advances in miniaturization and connectivity will allow health care practitioners to assess and test for cardiac conditions from remote and rural locations. • Clinical Integration: Troponin testing is included in several pathways and protocols for the evaluation of the emergent patient with chest pain. In 2025, many hospitals employed systems to perform repeated-measurement, sensitivity testing. It was expected that within the subsequent 3-5 years, greater consistency in the ordering of the tests by healthcare professionals would occur. In addition, the availability of the test would foster greater confidence in the evaluation and treatment of patients with potential myocardial infarctions. The challenges facing this market include: • Interpreting Results: There are numerous other conditions that can cause elevated levels of troponins including strenuous physical activity, sepsis, and renal and heart failure. In 2025, it was not uncommon for clinicians to rely on a series of troponin measurements over a period of time. It was expected that in the next 3-5 years, healthcare professionals would become less tolerant of the current level of uncertainty in clinical practice and would take steps to prevent unnecessary admissions and repeat testing. • Cost and Reimbursement: Healthcare facilities are challenged to control costs and improve the timeliness of testing. In 2025, it was not uncommon for a patient to undergo 2 or 3 troponin measurements. In the next 3-5 years, it was expected that improvements in tests and the equipment used to perform the testing would need to be achieved in order for healthcare facilities to improve the overall flow of patients and to reduce costs. • Barriers from Regulation and Standardization: Different requirements for calibration, reference ranges, and the units in which results are reported create barriers to the trade of medical devices. Also, variances in the requirements for marketing clearance and approval contribute to barriers to the trade of medical devices. As of 2025, device manufacturers were still required by regulators to establish assay-specific 99th percentile threshold limits. It is anticipated that in the next 3-5 years, regulatory requirements and the need for clinical validation would create a greater barrier to market for medical devices as compared to the lack of standardization for comparison of medical device results and the integration of medical device results across international boundaries. Due to the increasing global prevalence of cardiovascular disease and the increasing demand for time-critical emergency medical care, the medical need for medical devices to integrate timely and reliable cardiovascular diagnostic testing into medical practice is continually increasing. Competitive medical devices will likely integrate further with medical diagnostic instrumentation and medical information systems and become lower and lower cost. It is anticipated that regulatory and reimbursement environments will create significant barriers to the adoption of medical devices in various national healthcare systems. Medical devices that integrate diagnostics with clinical algorithms and protocols will likely be first to market. The medical devices that will be the most successful will integrate medical diagnostics with the goal of providing improved medical services to the largest population. List of Troponin Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies troponin market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the troponin market companies profiled in this report include- • Roche Diagnostics • Abbott Laboratories • Beckman Coulter • Response Biomedical • Vitro • Siemens Healthcare GmbH • Radiometer Medical ApS • bioMérieux SA • Thermo Fisher Scientific • Mitsubishi Chemical Europe Troponin Market by Segment The study includes a forecast for the global troponin market by product type, application, end use, and region. Troponin Market by Product Type [Value ($B) from 2019 to 2035]: • Troponin I • Troponin T • Troponin Complex • Others Troponin Market by Application [Value ($B) from 2019 to 2035]: • Myocardial Infarction • Acute Coronary Syndrome • Congestive Heart Failure • Cardiomyopathy • Others Troponin Market by End Use [Value ($B) from 2019 to 2035]: • Hospitals • Diagnostics Laboratories • Home Care • Others Troponin Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Troponin Market Expanding regulatory approval for high sensitivity assays, onsite manufacturing and automation are the main trends for the troponin market. Between 2025 and 2027, the focus for manufacturers is expanding the platforms to other analyzers and shortening the time for emergency department cardiac testing. According to Lucintel, these changes positively impact the market. • United States: Increasing regulatory approval for high sensitivity cardiac troponin assays, along with FDA guidance for medical devices, will positively impact the adoption of cardiac troponin tests by U.S. healthcare facilities in the next 3-5 years. • China: The Chinese FDA, the National Medical Products Administration, approved several high sensitivity cardiac troponin assays in 2025. The 14th Five-year plan for China will also positively impact the medical device manufacturing industry by 2025. • Germany: The Hospital Future Act provides €4.3 billion to digitalize hospitals, with implementation continuing beyond 2024. Meanwhile, Siemens Healthineers is expanding the Atellica platform in Europe. Greater lab automation and connected diagnostics will facilitate broader use of standardized troponin testing across German acute care. • India: The Production Linked Incentive scheme for medical devices will drive further investment in diagnostics, especially in troponin assay development and analyser manufacturing, up to 2026. We expect standardized troponin testing to become more prevalent in Indian hospitals beyond the major metros. • Japan: In 2025, the Japanese Ministry of Health, Labour and Welfare will continue to evaluate advanced cardiac troponins for reimbursement. Along with similar efforts by automating immunoassay, this will facilitate the faster adoption of type D troponins in Japan. Features of the Global Troponin Market Market Size Estimates: troponin market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: troponin market size by product type, application, end use, and region in terms of value ($B). Regional Analysis: troponin market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different product types, applications, end uses, and regions for the troponin market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the troponin market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the troponin market by product type (troponin i, troponin t, troponin complex, and others), application (myocardial infarction, acute coronary syndrome, congestive heart failure, cardiomyopathy, and others), end use (hospitals, diagnostics laboratories, home care, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?